Uniting Leading Drug Developers & Academics to Successfully Deliver siRNA into Extrahepatic Tissues
Building on the success of the 2022 summit, we are bringing the RNAi-Based Therapeutics Summit back with a refreshed agenda, and brand new content, and will showcase new companies that haven’t presented at this meeting in the past.
In March 2023, the 4th RNAi-Based Therapeutics Summit is returning to Boston to welcome 90+ technical and strategic expertise from Early Discovery, Preclinical, Clinical, Delivery, and Manufacturing to learn and network with pioneers in the space to turbocharge more RNAi therapies into the clinic and into extra-hepatic tissues.
With a brand new pre-conference focus day on evaluating next-generation delivery technologies, this summit offers the full end-to-end of RNAi drug development to support your own journey to fully realize the potential of siRNA.
With 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia, join us to discuss novel delivery modalities, next-generation chemistries, clinical updates scaling up and more.
Join the ever-growing audience of RNAi experts seeking to overcome the challenges of developing RNAi therapies that overcome barriers to extra-hepatic delivery to the CNS and beyond, improve selectivity, and fast-track candidates into, and through the clinic towards approval.
Here is a snapshot of our expert speakers:
Advisor - Genetic Medicine
Eli Lilly & Co.
Chief Scientific Officer